Melbourne, Australia;
2 June 2021 – Key EU Patent covering OBM-1701 Granted

Oculus Biomed Limited (“OBM”) is pleased to announce the European patent application which covers the OBM-1701, OBM’s leading novel drug candidate for treating wet-type age-related macular degeneration (wet-AMD) and its related analogues, has been allowed by the European Patent Office(“EPO”). Subsequent patent certification in European Countries, including Germany, France, United Kingdom, Italy, Spain & Switzerland, will be requested and granted. The term of such patent extends its patent protection to April 2036. Corresponding patent applications have already been granted in 6 other countries, including Australia, New Zealand, USA, Canada, Japan, South Korea, and Taiwan(R.O.C.). It is also allowed by The Chinese Patent Office on 7th April 2021. Applications are currently pending in Malaysia and Singapore, Hong Kong and Macau.